Revolution Medicines presented updated phase I/II data at AACR 2026 showing daraxonrasib, its oral RAS(ON) multi-selective inhibitor, with tumor control signals in previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC). The company reported findings across monotherapy and combination regimens alongside background updates from earlier late-stage work. The AACR presentation comes as RevMed continues to build momentum from its phase III success in a previously treated PDAC setting. In the new early-line dataset, investigators described response and survival metrics intended to inform the design and expectations of ongoing phase III efforts for first-line disease. The strategy aims to broaden the population benefit beyond a narrow mutation subset by using a mechanism designed to address multiple RAS states. In event-driven terms, the conference update keeps RevMed’s late-stage roadmap in focus for both clinicians and capital markets. Investors will likely watch for consistency of effect size across cohorts and for whether combination therapy improves durability in a disease where response rates have historically been modest.